6Hoofnagle JH, Di-Biscegle AM. Antiviral therapy of viral hepatitis.In: Galasso GJ, Whitley RJ, Merigan TC (Eds). Antiviral agents and viral diseases of man. 3rd ed. New York, Raven press, 1990,238～242
7Gary L, Davis MD. Current treatment for chronic hepatitis C. Rev GasDis, 2002, 1:59～72
8Davis GL. Current therapy for chronic hepatitis C. Gastroenterology,2000, 118:104～114
9Neuman AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interon-a therapy Science, 1998,282: 103～ 107
10Flamm SL. Chronic hepatitis C virus infection. JAMA, 2003, 289:2413--2417.
二级参考文献16
1Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869.
2Papatheodoridis GV, Papadimitropoulos VC, Hsdziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus- reated cirrhosis: a meta- analysis[J] .Aliment Pnarmaool Ther, 2001,15:689- 698.
3Kjaergard LL, Krogsgaard K, Gluud C. Interfern alfa with or without ribavirin for chronic hepatitis C: systematic review of randonmised trials[J].BMJ, 2001,323:1151 - 1155.
4Alberti A, Benvegnu L. Management of hepatitis[J] .J Hepatol, 2003,38(Suppl1): S1014 - S1 18.
5Poynard T, MdHutchison J, Davis GL, et al. Impact of interferon alfa - 2b and ribavirin on progression of liver fibrosiis in patients with chronic hepatitis C[J].Hepatology, 2000,32:1131 - 1137.
6Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the mangement of hepatitis C[J]. Gut, 2001, 49(Suppl I ): il - i12.
7Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review[J]. Hepatology, 2002, 36(5 Suppl 1 ):S135 - S144.
8Di Ciomm no V, Russo P, Rava L, etal. Interferon alpha in the treatment of chronic hepatitis C in children: a mmeta- analysis[J] .J Viral Hepat,2003,10:210 - 214.
9Fabrizi F, Dulai G, DixitV, et al. Meta- analysis: interfeorn for the treatment of chronic hepatitis C in dialysis patients[J] .Aliment Phamacol Ther, 2003,18:1071 - 1081.
10National Institute of Health Consensus Development Conference Panel Statenent. Management of hepatitis C[J].Hepatology, 2002,36(5 Suppl 1):S3- S20.
4Tamim H,Irani-Hakime N,Aoun JP,et al.Serop revalence of hepatitis C virus(HCV) infection among blood donors:a hosp ital-based study.Transfus Apheresis Sci,2001,24(1):29-35.
5Adinolfi LE,Utili R,Andreana A,et,al.Serum HCVRNA levels correlate with histological liver damage and concur with steatosis in propression of chronic hepatitis C.Dig Dis Sci,2001,46:1677-1683.
6Sabin CA,Emery V,Devereux HL,et al.Long-term patterns of hepatitis C virus RNA concentrations in a cohort of HIV seronegative men with bleeding disorders.J Med Virol,2002,68:68-75.
7Lee YS,Yoon SK,Chung ES,et al.The relationship of histologic activity to serum ALT,HCV RNA genotype and HCV RNA titers in chronic hepatitis C.J korean Med Sci,2001,16(5):585-591.
8Hagiwara H, Hayashi N, Mita E, et al. Quantitation of HCV RNA in serum of asymptomatic blood donors and patients with types Cchronic liver disease[J]. Hepatolo- gy,2011,79(9) :545-550.
9Kagawa T,Saito H,Tada S. ls hepatitis C virus cytpathic [J]. Lancet,2010,341 (4) :316-317.
10Zhang Sir, Liang XS, I.in SM, et al, Relation between vire- mia level and liver disease in patients with chronic HCV infection[J].China Natl J New Gastroenterol, 1996, 2 (41):115-117.
